Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Volitionrx (VNRX) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Volitionrx (VNRX) over the last 9 years, with Q3 2025 value amounting to -$3.6 million.

  • Volitionrx's Cash from Operations rose 3260.72% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.6 million, marking a year-over-year decrease of 4002.49%. This contributed to the annual value of -$25.9 million for FY2024, which is 4335.17% down from last year.
  • Volitionrx's Cash from Operations amounted to -$3.6 million in Q3 2025, which was up 3260.72% from -$6.3 million recorded in Q2 2025.
  • Volitionrx's 5-year Cash from Operations high stood at $6.4 million for Q4 2023, and its period low was -$8.7 million during Q1 2023.
  • Over the past 5 years, Volitionrx's median Cash from Operations value was -$5.8 million (recorded in 2022), while the average stood at -$5.0 million.
  • Over the last 5 years, Volitionrx's Cash from Operations had its largest YoY gain of 21109.72% in 2023, and its largest YoY loss of 34221.02% in 2023.
  • Volitionrx's Cash from Operations (Quarter) stood at -$4.4 million in 2021, then tumbled by 31.62% to -$5.8 million in 2022, then skyrocketed by 211.1% to $6.4 million in 2023, then plummeted by 184.24% to -$5.4 million in 2024, then skyrocketed by 33.16% to -$3.6 million in 2025.
  • Its Cash from Operations was -$3.6 million in Q3 2025, compared to -$6.3 million in Q2 2025 and -$4.3 million in Q1 2025.